poisar

Stocks · News reference

FDA Grants Fast Track Designation to Mavorixafor for Chronic Neutropenia

Fiscal.ai

The U.S. Food and Drug Administration has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading